|
COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy. |
|
|
Employment - TypeZero (I) |
Leadership - TypeZero (I) |
Travel, Accommodations, Expenses - Novo Nordisk; Tandem Diabetes Care (I) |
|
|
Consulting or Advisory Role - Jazz Pharmaceuticals |
|
|
Honoraria - Novartis; Pfizer; PSI |
Travel, Accommodations, Expenses - PSI |
|
|
Honoraria - Beckman Coulter |
Consulting or Advisory Role - Spectrum Pharmaceuticals |
Research Funding - Amgen; BioLineRx; Juno Therapeutics; Pfizer; Seagen |
Travel, Accommodations, Expenses - Amgen; Seagen |
|
|
Honoraria - Varian Medical Systems |
Speakers' Bureau - Varian Medical Systems |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Otonomy |
Travel, Accommodations, Expenses - Otonomy |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Sigma-Tau |
|
|
Consulting or Advisory Role - Adaptive Biotechnologies |
Travel, Accommodations, Expenses - Adaptive Biotechnologies |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Amgen; Amgen (I); Express Scripts; Merck (I); Pfizer (I) |
Honoraria - ERYTECH Pharma; Jazz Pharmaceuticals; Spectrum Pharmaceuticals |
Consulting or Advisory Role - Novartis |